Friday, November 28, 2014

TearLab Q3 revenue up 24%

TearLab Q3 revenue up 24%

November 5, 2014 by · Leave a Comment 

Tweet Third quarter net revenue for TearLab (NASDAQ:TEAR; TSX:TLB) totalled $5.2-million, up 24% from $4.2 million a year ago A net 118 TearLab Osmolarity systems were added to the company’s installed base in the third quarter. Of those, 50 systems were under the Masters Multi Unit Program, 21 were through its minimum use access programs, […]

Julie Speed joins TearLab as VP global marketing

Julie Speed joins TearLab as VP global marketing

October 6, 2014 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) has appointed Julie Speed to its senior management team as VP of global marketing. Her mandate will be leading global marketing functions for the complete TearLab portfolio, including its internal diagnostics product line and the OcuHub platform. Ms. Speed joins TearLab after 15 years of at Alcon Laboratories, where her previous […]

Study shows hyperosmolarity may impact cataract surgery planning

Study shows hyperosmolarity may impact cataract surgery planning

September 15, 2014 by · Leave a Comment 

Tweet Preliminary results of the TearLab (NASDAQ:TEAR; TSX:TLB) Cataract Study were presented today at the XXXIII Congress of the European Society of Cataract and Refractive Surgeons (ESCRS). The groundbreaking study evaluated the relationship of a hyperosmolar tear film on keratometry readings.  The study demonstrated that hyperosmolar patients demonstrated a wider variation in keratometry calculations between […]

TearLab reports interim results of DED prevalence study in UK

TearLab reports interim results of DED prevalence study in UK

September 4, 2014 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) has reported interim results of a multi-center dry eye disease (DED) prevalence study being carried out in the UK at four National Health Service (NHS) hospitals.  The study compared the effectiveness of the TearLab Osmolarity test to other traditional methods of diagnosing DED. Conducted under the auspices of the UK’s National […]

TearLab to unveil second generation tear testing platform

TearLab to unveil second generation tear testing platform

August 14, 2014 by · Leave a Comment 

Tweet At its analyst and investor day on Sept. 23, TearLab (NASDAQ:TEAR; TSX:TLB) plans to cover its current business and growth strategies, international market opportunities recent R&D activities, including development of a second-generation point-of-care tear testing platform. On the second quarter conference call earlier this month, CEO Elias Vamvaskas said most of the research has been […]

TearLab Q2 revenue climbs 42%

TearLab Q2 revenue climbs 42%

August 7, 2014 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) has reported second quarter revenue of $5-million, up 42% from $3.5-million in the year earlier quarter and an increase of 19% sequentially from $4.2-million in the 2014 first quarter. A net 171 TearLab Osmolarity systems were added to the company’s installed base in the second quarter. Of those, 126 systems were […]

Manoj Venkiteshwar joins TearLab as VP of medical affairs

Manoj Venkiteshwar joins TearLab as VP of medical affairs

July 14, 2014 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) announced the appointment of Manoj Venkiteshwar to its senior management team in the newly created position of VP of medical affairs. Dr. Venkiteshwar’s mandate will be the development and execution of a comprehensive academic and key opinion leaders (KOL) management strategy for the company. He joins TearLab from his current position as […]

TearLab, Cancer Genetics in Feltl’s Top Idea List for H2-2014

TearLab, Cancer Genetics in Feltl’s Top Idea List for H2-2014

July 8, 2014 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) and Cancer Genetics (NASDAQ:CGIX) have been included in Feltl & Co.’s Top Ideal List for the second half of 2014. Analyst Ben Haynor rates both stocks as “strong buys.” His price target for TearLab is $10.50 and $18.50 for Cancer Genetics. He said TearLab has first-mover advantage in point-of-care diagnostics for […]

TearLab posts 70% jump in Q1 revenue

TearLab posts 70% jump in Q1 revenue

May 8, 2014 by · Leave a Comment 

Tweet First quarter revenue for TearLab (NASDAQ:TEAR; TSX:TLB) totaled $4.2-million, up 70%, from $2.5-million a year ago. A total of 254 orders for TearLab systems were booked in the first quarter, of which 201 systems were under the company’s Masters Multi Unit Program, 40 were through its minimum use access programs, six were direct purchases […]

Survey finds high confidence in tear osmolarity testing

Survey finds high confidence in tear osmolarity testing

April 25, 2014 by · Leave a Comment 

Tweet A survey by Ophthalmic Consultants of Long Island conducted after TearLab (NASDAQ:TEAR; TSX:TLB) partnered with major dry eye organization, Sjögren’s Society, to promote Dry Eye Disease Awareness Month last year found a high degree of patient satisfaction in tear osmolarity testing. There were 278 eye clinics that participated in the survey and over 1,000 […]

Next Page »

Email Newsletters with Constant Contact
Google+